Your Pharmacogenomics Report: What to Ask Your Doctor

You uploaded your genetic data. You ran the pharmacogenomics analysis. You're staring at a report full of gene names like CYP2D6 and SLCO1B1 and metabolizer categories you've never heard of.

Now what?

Most people get a PGx report and do nothing with it. Not because they don't care, but because there's no clear next step. You can't prescribe yourself alternative medications. You can't adjust your own doses. The information is only useful when it reaches the person writing your prescriptions.

This guide is the bridge. Here's exactly how to turn your pharmacogenomics data into a conversation your doctor can act on.

First: understand the four metabolizer types

Your PGx report classifies you into metabolizer categories for each gene. Think of these as your body's processing speed for specific drugs.

Ultra-Rapid Metabolizer -- Your body breaks down the drug faster than normal. Standard doses may be cleared too quickly to be effective. You might need a higher dose or a different drug entirely. For prodrugs (drugs that need to be activated by the enzyme), ultra-rapid metabolism can be dangerous -- codeine, for example, gets converted to morphine too quickly in ultra-rapid metabolizers, risking overdose.

Normal Metabolizer (Extensive Metabolizer) -- Standard doses work as expected. This is what most prescribing guidelines assume you are.

Intermediate Metabolizer -- Your body processes the drug slower than normal. You may experience stronger effects or more side effects at standard doses. A dose reduction may be appropriate.

Poor Metabolizer -- Your body processes the drug very slowly or barely at all. Standard doses can accumulate to toxic levels for drugs eliminated by this enzyme. For prodrugs that require activation, the drug may simply not work.

The analogy: Imagine a factory assembly line. Ultra-rapid metabolizers run the line at double speed -- things get processed so fast they might fly off the belt. Normal metabolizers run at the expected speed. Intermediate metabolizers run at half speed -- things pile up a bit. Poor metabolizers have the line nearly stopped -- everything backs up.

The same drug, the same dose, can have dramatically different effects depending on where you fall on this spectrum.

The 5 gene-drug interactions everyone should know

These are the interactions with the highest clinical impact -- the ones where getting it wrong has real consequences.

1. CYP2D6 + Codeine / Tramadol

What happens: CYP2D6 converts codeine into morphine and tramadol into its active metabolite. Poor metabolizers get no pain relief from either drug. Ultra-rapid metabolizers convert too much, too fast -- this has caused fatal respiratory depression, particularly in children.

Who's affected: 5-10% of Caucasians are poor metabolizers. 1-2% of Caucasians and up to 29% of certain East African populations are ultra-rapid metabolizers.

What to ask your doctor: "My PGx test shows I'm a [your status] metabolizer of CYP2D6. If I ever need opioid pain management, can we note in my chart that codeine and tramadol should be avoided? Alternatives like oxycodone or morphine don't depend on CYP2D6."

Why it matters: This is the most commonly encountered PGx interaction because codeine is prescribed so frequently -- after dental procedures, minor surgeries, injuries. You want this on your chart before you need it, not while you're in post-op.

2. CYP2C19 + Clopidogrel (Plavix)

What happens: Clopidogrel is a prodrug that requires CYP2C19 to become active. It prevents blood clots in patients who've had heart attacks, strokes, or stent placement. Poor metabolizers don't activate the drug effectively, leaving them at significantly increased risk of clot formation. This interaction can be life-or-death.

Who's affected: Approximately 2-3% of Caucasians and 12-23% of Asian populations are CYP2C19 poor metabolizers.

What to ask your doctor: "I'm a CYP2C19 [your status] metabolizer. If I ever need antiplatelet therapy, clopidogrel may not be fully effective for me. Can we note that prasugrel or ticagrelor should be considered as alternatives?"

Why it matters: The FDA added a black box warning to clopidogrel in 2010 about CYP2C19 poor metabolizers. Despite this, PGx testing before prescribing clopidogrel is still not routine at most hospitals. Having this information already in your chart could prevent a clotting event.

3. SLCO1B1 + Simvastatin

What happens: SLCO1B1 is a transporter gene that moves simvastatin into the liver for processing. Certain variants (particularly the *5 allele) reduce this transport, causing simvastatin to accumulate in the bloodstream and muscle tissue. The result: statin-associated myopathy -- muscle pain, weakness, and in severe cases, rhabdomyolysis (muscle breakdown that can damage the kidneys).

Who's affected: Roughly 15-20% of people carry at least one copy of the SLCO1B1*5 variant.

What to ask your doctor: "My PGx report shows I have the SLCO1B1*5 variant. If I need a statin, can we start with rosuvastatin or pravastatin instead of simvastatin? These statins aren't affected by SLCO1B1 transport."

Why it matters: Simvastatin is one of the most widely prescribed drugs in the world. Muscle pain is the number one reason patients stop taking statins, and SLCO1B1 status is a major predictor of who will experience it. Knowing this upfront can mean the difference between a statin you tolerate and one you quit after three weeks.

4. DPYD + Fluorouracil (5-FU) / Capecitabine

What happens: DPYD produces the enzyme that breaks down fluoropyrimidine chemotherapy drugs (5-FU and capecitabine, used in colorectal, breast, and other cancers). Patients with DPYD deficiency can experience severe, potentially fatal toxicity at standard chemotherapy doses -- including neutropenia, mucositis, diarrhea, and death.

Who's affected: 3-8% of the population carries a partial DPYD deficiency. Complete deficiency is rare (0.1-0.5%) but is associated with mortality rates of up to 10-20% when standard-dose fluoropyrimidines are given.

What to ask your doctor: "I have a DPYD variant identified on my PGx test. If I'm ever prescribed 5-FU or capecitabine, my dose needs to be reduced or an alternative chemotherapy regimen should be considered. Can this be added to my chart?"

Why it matters: This is arguably the most dangerous interaction on this list. Pre-treatment DPYD testing is now recommended by CPIC guidelines and is becoming standard of care at major cancer centers, but it is not yet universal. Having this information in your medical record before a cancer diagnosis ensures it won't be overlooked.

5. HLA-B*57:01 + Abacavir

What happens: HLA-B*57:01 is an immune system gene variant that causes a severe hypersensitivity reaction to abacavir, a common HIV medication. The reaction includes fever, rash, nausea, and can be fatal if the drug is continued or re-introduced after stopping.

Who's affected: 5-8% of Caucasians, 2-3% of African Americans, and less than 1% of Asian populations carry HLA-B*57:01.

What to ask your doctor: "My genetic test shows I'm [positive/negative] for HLA-B*57:01. If I ever need HIV treatment, abacavir should be avoided."

Why it matters: This is actually a PGx success story -- HLA-B*57:01 testing before prescribing abacavir is now standard of care and has nearly eliminated hypersensitivity reactions. But if you already know your status from a consumer genetic test, it's worth having it documented.

How to start the conversation

You don't need to memorize gene names or deliver a lecture. Here's a script that works:

Opening line: "I recently got a pharmacogenomics test that analyzes how my body metabolizes medications. I have a one-page summary that shows my results. Can I share it with you so we can note the relevant findings in my chart?"

If you're currently on medications: "The report also includes a medication scan that checks my current prescriptions against my genetic profile. There are [X] interactions flagged. Can we review those together?"

If you're not currently on any affected medications: "I'm not on any affected medications right now, but I'd like my PGx results on file so they can be referenced if my prescriptions change in the future."

The key phrase: "Can we note this in my chart?" This is the single most important thing you can say. If the information is in your medical record, any provider who prescribes for you in the future -- including emergency physicians and surgeons -- can see it.

If your doctor isn't familiar with pharmacogenomics

This happens. PGx education in medical school has historically been minimal, and many practicing physicians have limited exposure to it. This is not a reason to dismiss the information or the doctor.

What to do:

• Ask for a pharmacist consult. Clinical pharmacists, especially those at academic medical centers, are often more familiar with PGx interpretation than physicians. Many hospitals now have PGx-trained pharmacists on staff.
• Request a referral. Some medical systems have dedicated pharmacogenomics clinics. These are becoming more common at major medical centers.
• Provide the CPIC guidelines. The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes free, peer-reviewed guidelines for every major gene-drug pair. They're available at cpicpgx.org. Vitalix includes links to the relevant CPIC guideline for each flagged interaction in your report.
• Be patient. Your doctor may want to verify your results through a clinical-grade PGx test before making prescribing changes. This is reasonable and appropriate. Consumer genetic tests are highly accurate for the variants they cover, but a clinical confirmation adds another layer of confidence.

Print the report. Bring the report.

Vitalix generates a medication scan report that checks your active medications against your full PGx profile. It shows:

• Your metabolizer status for each of the 30 analyzed genes
• Any current medications that have known interactions with your genotype
• The severity level of each interaction (informational, moderate, high)
• Alternative medications to discuss with your prescriber
• Links to CPIC guidelines for clinical reference

Print it. Physically. Hand it to your doctor. Medical records systems are not set up to accept patient-uploaded PDFs in most cases, but a printed report that your doctor can scan into your chart works.

The goal is simple: get this information from your phone into your medical record, where it can influence prescribing decisions for the rest of your life.

Your genome doesn't change. A PGx report done once is valid forever. The 30 minutes it takes to discuss it with your doctor is a one-time investment that could prevent a wrong medication from being prescribed years or decades from now.

That's a conversation worth having.